

Jonas Cicenas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6876493/publications.pdf>

Version: 2024-02-01

25
papers

1,454
citations

516561

16
h-index

580701

25
g-index

25
all docs

25
docs citations

25
times ranked

2914
citing authors

#	ARTICLE	IF	CITATIONS
1	SGK1 in Cancer: Biomarker and Drug Target. <i>Cancers</i> , 2022, 14, 2385.	1.7	8
2	Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020. <i>Cancers</i> , 2021, 13, 947.	1.7	10
3	Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 972.	1.7	4
4	Non-Coding RNAs in Glioma. <i>Cancers</i> , 2019, 11, 17.	1.7	98
5	Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer. <i>Anticancer Research</i> , 2018, 38, 5759-5765.	0.5	21
6	Kinases and Cancer. <i>Cancers</i> , 2018, 10, 63.	1.7	93
7	JNK, p38, ERK, and SGK1 Inhibitors in Cancer. <i>Cancers</i> , 2018, 10, 1.	1.7	170
8	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. <i>Medical Oncology</i> , 2017, 34, 26.	1.2	94
9	The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 726-733.	1.0	29
10	Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1. <i>Medical Oncology</i> , 2017, 34, 176.	1.2	7
11	KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. <i>Cancers</i> , 2017, 9, 42.	1.7	193
12	Current Role of Proteomics in Pancreatic Cancer Biomarkers Research. <i>Current Proteomics</i> , 2016, 13, 68-75.	0.1	4
13	Multi-kinase inhibitors, AURKs and cancer. <i>Medical Oncology</i> , 2016, 33, 43.	1.2	36
14	Metabolomics in pancreatic cancer biomarkers research. <i>Medical Oncology</i> , 2016, 33, 133.	1.2	35
15	The Aurora kinase inhibitors in cancer research and therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1995-2012.	1.2	44
16	Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 219-232.	1.1	13
17	JNK inhibitors: is there a future?. <i>MAP Kinase</i> , 2015, 4, .	0.3	14
18	Roscovitine in cancer and other diseases. <i>Annals of Translational Medicine</i> , 2015, 3, 135.	0.7	99

#	ARTICLE	IF	CITATIONS
19	Highlights of the Latest Advances in Research on CDK Inhibitors. <i>Cancers</i> , 2014, 6, 2224-2242.	1.7	104
20	The CDK inhibitors in cancer research and therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1409-1418.	1.2	210
21	Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor. <i>Cancers</i> , 2010, 2, 153-164.	1.7	7
22	The potential role of the EGFR/ERBB2 heterodimer in breast cancer. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 607-616.	2.4	9
23	Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. <i>European Journal of Cancer</i> , 2006, 42, 636-645.	1.3	59
24	Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. <i>Proteomics</i> , 2006, 6, 1427-1436.	1.3	39
25	Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. <i>Breast Cancer Research</i> , 2005, 7, R394-401.	2.2	54